SECOND QUARTER OF 2021 (APR – JUN)

Net sales amounted to SEK 36.6 million (20.6), corresponding to an increase of 77 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 45 percent.

Operating profit amounted to SEK 2.2 million (0.8).

Net profit amounted to SEK 3.5 million (loss 0.2), corresponding to earnings per share of SEK 0.09 (loss 0.01).

Cash flow from operating activities amounted to SEK 9.4 million (2.6). As of June 30, 2021, cash and cash equivalents amounted to SEK 267.3 million (68.4).

FIRST HALF OF 2021 (JAN – JUN)

Net sales amounted to SEK 73.8 million (40.3), corresponding to an increase of 83 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 49 percent.

Operating profit amounted to SEK 4.5 million (0.0). The outcome includes acquisition costs of SEK 6.0 million.

Net profit amounted to SEK 5.0 million (loss 0.9), corresponding to earnings per share of SEK 0.13 (loss 0.03).

Cash flow from operating activities amounted to SEK 0.5 million (outflow 2.6).

In January, Mimic Technologies Inc., was acquired, with operations in robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The transfer of ownership took place on January 27.

FOLLOWING THE CLOSE OF THE PERIOD

On July 28, it was announced that Surgical Science had entered into an agreement to acquire Simbionix. On August 16, an Extraordinary General Meeting was held, at which the directed share issue to finance the acquisition was approved. The transfer of ownership is expected within short.

Gothenburg, Sweden, August 20, 2021
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science is headquartered in Gothenburg, Sweden and present in Stockholm, Sweden, as well as in Seattle, Washington, in the US. Through sales offices in the US, France, China and UAE as well as a global network of distributors, Surgical Science maintains a presence in most markets around the world. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Telephone: 08-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-08-20 08:30 CEST.

Attachments

210820 Q22021 ENG

© Modular Finance, source Nordic Press Releases